Brief: Replimune Group Q1 Net Income USD -86.693 Million
07/08/2025 13:00
Overview Replimune fiscal Q1 net loss widens to $86.7 mln from $53.8 mln yr ago Company's cash position decreased to $403.3 mln due to clinical development costs Outlook Replimune expects cash to fund operations into Q4 2026 Result Drivers R&D EXPENSES - Increased due to scaling operations for RP1 commercial launch and higher personnel-related costs SG&A EXPENSES - Rose significantly due to increased personnel and stock-based compensation costs CASH DECREASE - Cash position fell due to clinical development costs and operating activities Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q1 Net Income | -$86.69 mln | ||
| Q1 Basic EPS | -$0.95 | ||
| Q1 Cash & Investments | $403.30 mln | ||
| Q1 Operating Expenses | $90.42 mln | ||
| Q1 Operating Income | -$90.42 mln |
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly